egfr phosphosite (Santa Cruz Biotechnology)
Structured Review

Egfr Phosphosite, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 2423 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cell+based+proteome+array+screen/EGFR/pmc04841779-402-0-10
Average 96 stars, based on 2423 article reviews
Images
1) Product Images from "Time-resolved multimodal analysis of Src Homology 2 (SH2) domain binding in signaling by receptor tyrosine kinases"
Article Title: Time-resolved multimodal analysis of Src Homology 2 (SH2) domain binding in signaling by receptor tyrosine kinases
Journal: eLife
doi: 10.7554/eLife.11835
Figure Legend Snippet: ( A ) Representative anti-pY Western (upper panel) and far-Western blots (next four panels) of 60-min EGF stimulation time-course. Far-Westerns using GRB2, SHP2-N, NCK1 and RASGAP-N are shown to illustrate major binding patterns identified (see B ). Additional SH2 blot data are provided in . Immunoblotting with antibodies to EGFR and tubulin was used to confirm equal loading. ( B ) Hierarchical clustering of SH2 domains on the basis of binding to four major phosphoproteins (EGFR, GAB1, p130CAS, and SHCA). Signal was normalized to maximum band intensity across all time points and all bands for each probe replicate. Then data for each phosphoprotein was averaged in a probe specific manner (red represents greater percentage of total signal, max = 1, min = 0). Names of SH2/PTB domain probes are indicated on the right. Colored boxes represent SH2 clusters defined by un-centered correlation coefficient >0.85. DOI: http://dx.doi.org/10.7554/eLife.11835.004
Techniques Used: Western Blot, Binding Assay
Figure Legend Snippet: ( A ) EGFR, ( B ) p130CAS, ( C ) GAB1, and DOI: http://dx.doi.org/10.7554/eLife.11835.006
Techniques Used:
Figure Legend Snippet: ( A ) Hierarchical clustering of relative SH2 specificity. Values were obtained by subtracting percent bound by pY from percent bound by each SH2 for each time point. Red represents binding greater than pY and green represents binding less than pY. Relative SH2 specificity value = %Band intensity SH2 at time x - %Band intensity anti-pY at time x. ( B ) Hierarchical clustering of SH2 binding to EGFR band (normalized to maximum, max=1, min=0) for 60-min time-course. ( C ) Hierarchical clustering of EGFR phosphosite-specific Western blotting quantifications (normalized to maximum, max=1, min=0) for 60-min time-course. ( D ) and ( E ) Plots comparing the EGFR phosphosite kinetics and SH2 binding kinetics for SH2 domains and their canonical binding motifs ( D , CRKL and pY992, R 2 =0.81; E, GRB2 and pY1168, R 2 =0.91). ( F ) Plot comparing total EGFR phosphorylation (pY EGFR band) with SHCA PTB binding (R 2 =0.89). R-squared values were calculated by plotting normalized pY Western intensity against normalized SH2 binding FW intensity. pY EGFR quantifications consist of data from a single experiment.( G ) pERK1 and pERK2 pY/pT activation site phosphorylation kinetics following stimulation with EGF. Lines represent average of two technical replicates. DOI: http://dx.doi.org/10.7554/eLife.11835.007
Techniques Used: Binding Assay, Phospho-proteomics, Western Blot, Activation Assay
Figure Legend Snippet: Eight time points; 0, 0.167, 0.5, 1, 1.5, 3, 10 and 30 min post-EGF were analyzed. Immunoblotting with antibodies to EGFR and tubulin was used to confirm equal loading. DOI: http://dx.doi.org/10.7554/eLife.11835.009
Techniques Used: Western Blot
Figure Legend Snippet: ( A ) Venn diagram showing overlap of significant gene ontologies for proteins containing peptides whose phosphorylation was enhanced or unchanged by EGF (p < 0.05, Bonferroni corrected). The number of unique or overlapping ontologies observed for each protein set is indicated within the diagram. GO terms listed represent the three largest GO parent terms returned by REVIGO . ( B ) Amino acid frequency logos for sites whose phosphorylation was enhanced (upper) and unchanged (lower) by EGF stimulation. Background data is PhosphoSitePlus pY database. ( C–F ) Relative phosphopeptide abundance for peptides derived from EGFR ( C ), GAB1 ( D ), SHCA ( E ) and p130CAS (BCAR1) ( F ). Specific phosphopeptide sequences are listed. Results are average of three biological replicates. DOI: http://dx.doi.org/10.7554/eLife.11835.008
Techniques Used: Phospho-proteomics, Derivative Assay
Figure Legend Snippet: ( A-C ) TIRF images of additional fluorescently tagged SH2 domains before and after EGF stimulation. A) GAB1 binding domains (SHP2-NC) ( B ) EGFR binding domains (GRB7) and ( C ) p130CAS binding domains (CRK, RASGAP-NC). Domains are labeled according to clustering results from . Post-EGF images were taken ~40min after stimulation. Scale bars = 10 μm ( D ) Correlation plot of SH2 domain probe diffusion rate ( D , y-axis) and recruitment time constant (τ, x-axis). Data for SHP2-C was an outlier and was removed from the plot for clarity. Error bars for τ values represent SEM (see ). DOI: http://dx.doi.org/10.7554/eLife.11835.011
Techniques Used: Binding Assay, Labeling, Diffusion-based Assay
Figure Legend Snippet: ( A ) Representative white light ( top panel ) and epifluorescence images ( lower panel ) of GRB2 SH2-tdEOS transfected A431 cells that were used to determine total cell number, transfection efficiency and relative expression level. Insert ( upper panel) shows representative DIC image of nonadherent cells used to determine cell volume. ( B ) Histogram of individual cell GRB2 SH2-tdEOS expression levels. Left skew in expression was compensated for in the final calculation. ( C ) Anti-GRB2 SH2 blot used to calculate the average concentration of GRB2 SH2-tdEOS (6.5 μM) and endogenous GRB2 (1.5 μM). Concentrations were determined by using bacterially produced GST-GRB2 SH2 fusion as standard (right side of the blot). ( D ) Anti-pY blot showing EGF-induced EGFR phosphorylation and phosphorylation standard titration used to calculate the cellular concentration of phosphorylated EGFR sites. Concentrations were determined using a highly phosphorylated recombinant ABL standard with a known pY concentration (right side of the blot). ( E ) Representative z-axis cross-sections of fixed A431 cells immunostained with anti-pY. The images and traces were obtained from the same cell along the x- and y-axes. White block indicates the quantified area. Curves represent an average of multiple line scan quantifications across an individual cell membrane. ( F ) Apical and basal pY levels following EGF stimulation as measured by immunofluorescence. Intensity measurements were averaged from two independent experiments; a total of at least seven cells were quantified for each time point. Error is SEM for all data points. ( G ) Ratio of apical to basal phosphorylation following stimulation with EGF. DOI: http://dx.doi.org/10.7554/eLife.11835.013
Techniques Used: Transfection, Expressing, Concentration Assay, Produced, Phospho-proteomics, Titration, Recombinant, Blocking Assay, Membrane, Immunofluorescence
Figure Legend Snippet: Upper left: three cell lines expressing wt EGFR (A431; Cos1 African green monkey kidney fibroblast cells; H226 human lung squamous cell carcinoma cells) were stimulated with 1 ng/ml EGF for 10 min. Expression and tyrosine phosphorylation of EGFR were determined by immunoblotting with anti-EGFR and anti-pY antibodies. Upper right and lower panels: proliferation assay results for A431, Cos1, and H226 cells. Cells in 96-well plates were incubated with control (0.1% FBS), 0.1–25 ng/ml EGF, or 10% FBS medium up to 72 hr as indicated in the inset. Cell proliferation was determined with CYQUANT direct reagents as described in Methods. Fold changes in normalized fluorescence values at 0 hr, 24 hr, and 72 hr after treatment are shown. Asterisks indicate a significant difference between treatments at 72 hr (p<0.0001, one-way ANOVA). Note that in A431 cells, 1 ng/ml EGF is mitogenic while 25 ng/ml EGF suppresses growth/survival. EGF is not mitogenic in Cos1 or H226 cells under conditions used here. DOI: http://dx.doi.org/10.7554/eLife.11835.015
Techniques Used: Expressing, Phospho-proteomics, Western Blot, Proliferation Assay, Incubation, Control, CyQUANT Assay, Fluorescence
Figure Legend Snippet: ( A ) Representative anti-pY immunoblot (upper panel) and Grb2 SH2 far-western blot (lower panel) of A431 cells stimulated with 1 ng/mL EGF and flash frozen at 22 discrete time points. ( B ) Quantification of EGFR tyrosine phosphorylation kinetics (from anti-pY immunoblot) in A431 cells treated with 1 ng/mL EGF (n=2 biological replicates) and 25 ng/mL EGF (n=3 biological replicates). ( C ) Anti-pY immunoblot of A431 cells stimulated with 1 ng/mL and 25 ng/mL EGF at 0, 1.5 and 10 min. EGFR phosphorylation was 5.4 +/- 0.4 fold greater in cells stimulated with 25 ng/mL (normalized for EGFR expression, error = SEM). No difference was observed in prestimulation EGFR phosphorylation after normalization. ( D ) Comparison of Grb2 SH2 binding site phosphorylation kinetics (GST-Grb2 SH2 FW, black; time constant τ = 54.6 +/- 1.4 s, n=2 biological replicates) and Grb2 SH2 in vivo membrane recruitment kinetics (tdEOS-GRB2 SH2 TIRF, red; time constant τ = 116.7 +/- 2.3 s, n=2 biological replicates). DOI: http://dx.doi.org/10.7554/eLife.11835.016
Techniques Used: Western Blot, Far Western Blot, Phospho-proteomics, Expressing, Comparison, Binding Assay, In Vivo, Membrane
Figure Legend Snippet: pervanadate (PV) treated cells. Representative GRB2 SH2 far-Western and anti-pY (PY100) immunoblots for EGF and PV treated cells. Immunoblotting with antibodies to EGFR and actin was used to confirm equal loading. DOI: http://dx.doi.org/10.7554/eLife.11835.022
Techniques Used: Western Blot
Figure Legend Snippet: CRK SH2 shows little or no binding to the EGFR band in COS1 cells. DOI: http://dx.doi.org/10.7554/eLife.11835.018
Techniques Used: Binding Assay
Related Articles
Membrane:Article Title: Butyrate Silences MUC5AC in Airway Epithelial Cells Through Histone Deacetylation at Its Promoter Region Article Snippet: .. The membrane was blocked with 5% non-fat dry milk and probed with antibodies against anti-phospho-ERK1/2 (Cell Signaling Technology, Beverly, MA, USA), Article Title: Butyrate Silences MUC5AC in Airway Epithelial Cells Through Histone Deacetylation at Its Promoter Region. Article Snippet: .. The membrane was blocked with 5% non-fat dry milk and probed with antibodies against anti-phosphoERK1/2 (Cell Signaling Technology, Beverly, MA, USA), Cell-Signaling:Article Title: Butyrate Silences MUC5AC in Airway Epithelial Cells Through Histone Deacetylation at Its Promoter Region Article Snippet: .. The membrane was blocked with 5% non-fat dry milk and probed with antibodies against anti-phospho-ERK1/2 (Cell Signaling Technology, Beverly, MA, USA), Article Title: Transcriptomic Analysis of the Newborn Mammary Gland Identifies Prenatal Ethanol-Induced Remodeling of Insulin Signaling and Enhanced Proliferative Programming Article Snippet: .. Proteins examined included IRS1(#3407), phospho-IRS1 (Ser612) (#3203), phospho-IRS1 (Tyr895) (#3070), phospho-Akt1 (Ser473) (#4060), ErbB3 (#12708), phospho-ERK1/2 (Thr202/Tyr204) (#9101) were purchased from Cell signaling Technology, Knock-Out:Article Title: Harnessing semen-derived exosomes for noninvasive fundus drug delivery: A paradigm for exosome-based ocular fundus therapeutics. Article Snippet: Samples were loaded by a C18 column (15 cm × 75 μm) on an EASY- nLC 1200 system (Thermo Fisher Scientific, USA). .. other:Article Title: Harnessing semen-derived exosomes for noninvasive fundus drug delivery: A paradigm for exosome-based ocular fundus therapeutics Article Snippet: Key signaling nodes [e.g., EGFR/phosphorylated EGFR (pEGFR), Src/pSrc, MLCK, and MLC/pMLC] were analyzed to confirm pathway-specific inhibition on barrier integrity; Anti-EGFR (1:1000; Abcam, USA, no. Ab32077), anti-pEGFR (1:1000; Abcam, USA, no. Ab134005 ), anti-Src (1:1000; Abcam, USA, no. Ab109381 ), anti-pSrc (1:1000; Abcam, USA, no. Ab4816), anti-MLCK (1:1000; Abcam, USA, no. Ab314185 ), anti-MLC (1:1000; Abcam, USA, no. Ab92721), anti-pMLC (1:1000; Cell Signaling Technology, USA, no. 3672S), anti–glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (1:1000; Abcam, USA, no. Ab8245). |